We used a new combination chemotherapy with nedaplatin (CDGP) and 5-fluorouracil (5-FU) in eleven fresh patients with oral squamous cell carcinomas. 5-FU was administered at a dose of 1,000 mg/body by continuous infusion for 24 hours on days 1 to 5. CDGP was administered at a dose of 80 or 100 mg/m2 by drip infusion for 120 minutes on day 5. The response rates of total (1- or 2-course) and 2-course group were 54. 5% and 83.3%, respectively. Adverse drug reactions were limited to two cases of grade 3 toxicity with anorexia. The combination chemotherapy with 5-FU and CDGP in place of cisplatin and 5-FU seemed to play an important role as neo-adjuvant chemotherapy for oral squamous cell carcinomas.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effect of Oral Inflammatory Burden on Size and Stage of Oral Tongue Cancer.
Oral Dis
December 2024
Department of Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland.
Objective: Oral tongue squamous cell carcinoma is an aggressive life-threatening disease, the prognosis of which is affected by tumor stage and size. We retrospectively studied whether oral inflammatory burden and established tongue carcinoma etiological factors exert an impact on tumor size and stage.
Materials And Methods: Medical records of 183 subjects diagnosed with tongue carcinoma at Helsinki University Hospital were investigated.
The role of long non-coding RNA LINC00839 in oral squamous cell carcinoma based on bioinformatics and experimental research.
Sci Rep
December 2024
Department of Clinical Biochemistry, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
This study explores the role of LINC00839 and its potential interaction with the miR-195-5p/cyclin E1 (CCNE1) axis in oral squamous cell carcinoma (OSCC). Using The Cancer Genome Atlas, we analyzed lncRNA, miRNA, and mRNA sequencing data for OSCC. Different online tools were applied to detect lncRNA-related miRNAs and their target mRNAs, forming a lncRNA/miRNA/mRNA axis.
View Article and Find Full Text PDFCorrigendum to "The first attempt in synthesis, identification, and evaluation of SEPT9 inhibitors on human oral squamous carcinomas" [Bioorg. Chem 154 (2025) 108068].
Bioorg Chem
December 2024
School of Pharmacy, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan. Electronic address:
Adjuvant Intensity Modulated Radiation Therapy With a Pedicled Flap Reconstruction in Oral Cavity Squamous Cell Carcinomas: Implications on Target Delineation.
Head Neck
December 2024
Department of Head & Neck Surgery, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
Objectives: To address controversies regarding target volume delineation for adjuvant intensity-modulated radiation therapy for oral cavity squamous cell carcinoma with pedicled flap reconstruction and elective nodal irradiation (ENI).
Materials And Methods: During target volume delineation, the primary tumor bed was the pre-surgical gross tumor volume with an additional isotropic margin of 5-10 mm. Additionally, the flap and body tissue junction were given a margin of 5-10 mm (if not already given).
Submandibular Gland Flap Reconstruction for Oropharyngeal Defects After Transoral Robotic Surgery (TORS).
Head Neck
December 2024
Department of Otolaryngology-Head & Neck Surgery, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Background: To describe utilization and outcomes of submandibular gland flap (SGF) reconstruction after transoral robotic surgery (TORS) for oropharyngeal squamous cell carcinoma (OPSCC).
Methods: A multi-institutional retrospective case series of patients who underwent TORS for OPSCC followed by SGF reconstruction with harvest via transcervical approach from 1/1/2016 to 4/1/2023.
Results: In total, 14 patients underwent SGF reconstruction after TORS for OPSCC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!